DR. MAINGA HAMALUBA
DR. MAINGA HAMALUBA
Head of Clinical Research
My responsibilities include providing leadership and coordination for clinical research and trials as well as monitoring, project management, database support and sponsorship for KWTRP investigator-led trials. I trained as a Paediatrician in Oxford and first started working in clinical trials over 15 years ago. My research career started in Oxford followed by a 6-month Wellcome Trust visiting fellowship to the KEMRI-Wellcome Trust programme in 2006 and a return to Kenya in 2016. My work in Kathmandu, Nepal and Oxfordshire focused on the population biology and vaccinology of Streptococcus pneumoniae in pre-school children. With a team of Nepali scientists, we conducted a vaccine trial in infants which informed and led to the introduction of the 10-valent pneumococcal conjugate vaccination schedule in Nepalese infants. My research interests continue focus on vaccine and translational research in paediatric and neonatal care at KEMRI-Wellcome. I am fortunate to work with a group of leading scientists in the department and across the programme where we take a multi-disciplinary approach tov improving child health and influencing policy.
This covers a broad spectrum of work including critical care, vaccinology, and human infection studies. I am Principal Investigator in the clinical development pipeline of candidate malaria (R21/MM) and shigella (S4V01) vaccines. I have clinical oversight of the largest human malaria challenge study and with plans underway for malaria transmission-blocking studies and shigella challenge models with Dr Melissa Kapulu. I work on optimising supply and costs of vaccines for Yellow Fever and pneumococcal vaccines with Prof George Warimwe, Prof Anthony Scott and Prof Katherine Gallagher. My portfolio of work on malaria includes a collaboration with Prof Arjen Dondorp (MORU) evaluating triple-artemisinin combination drugs in uncomplicated malaria, and a programme of work to improve management of severe malaria across Africa with Prof Kath Maitland. More recently my work has focused on addressing the pandemic response to the COVID-19 pandemic with an international consortium led by Prof. George Warimwe nationally. We have partnered with our colleagues in MORU once more to address the current pandemic through the implementation of the CoPCoV trial in Kenya led by Dr Anthony Etyang.
Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial
Hamaluba M, Kandasamy R, Upreti SR, Subedi GR, Shrestha S, Bhattarai S, Gurung M, Pradhan R, Voysey M, Gurung S, Pradhan S, Thapa AK, Maharjan R, Kiran U, Kerridge SA, Hinds J, van der Klis F, Snape MD, Murdoch DR, Kelly S, Kelly DF, Adhikari N, Thorson S, Pollard AJ.
Lancet Infect Dis. 2015; : 405-14
A cross-sectional observational study of pneumococcal carriage in children, their parents, and older adults following the introduction of the 7-valent pneumococcal conjugate vaccine
Hamaluba M, Kandasamy R, Ndimah S, Morton R, Caccamo M, Robinson H, Kelly S, Field A, Norman L, Plested E, Thompson BAV, Zafar A, Kerridge SA, Lazarus R, John T, Holmes J, Fenlon SN, Gould KA, Waight P, Hinds J, Crook D, Snape MD, Pollard AJ.
Medicine(Baltimore). 2015; : e335
Controlled Human Malaria Infection in Semi-Immune Kenyan Adults (CHMI-SIKA): a study protocol to investigate in vivo Plasmodium falciparum malaria parasite growth in the context of pre-existing immunity
Kapulu MC, Njuguna P, Hamaluba MM; CHMI-SIKA Study Team.
Wellcome Open Res. 2019; : 155
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B,Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O’Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group.
Lancet. 2020; : 99-111.